Dutasteride for FFA: What Hairline Stability Means

A hairline can remain in the same position without returning to its former position. That distinction matters when reading about dutasteride for frontal fibrosing alopecia (FFA).

FFA causes inflammation and scarring around hair follicles, often affecting the front, temples and eyebrows. Once a follicle is completely destroyed, treatment cannot make it grow hair again. A dermatologist may therefore aim to prevent further loss. Examination, and sometimes a biopsy, helps establish the diagnosis.¹

What the 224-patient study counted

A retrospective study published in 2021 included 224 patients, 222 of them women. Median follow-up was 24 months. The published abstract reported these 12-month stabilization rates, in front/right-temple/left-temple order:²

Group	Stable hairline
Dutasteride, 148 patients	62% / 64% / 62%
Other systemic medicines, 20 patients	60% / 35% / 35%
No systemic medicine, 56 patients	30% / 41% / 38%

The accepted manuscript specifies that everyone also received topical minoxidil and clobetasol. The last group therefore did not go without treatment.²

Treatment was not randomized. Some patients declined oral medicines; prescribing also reflected medical history. Those differences can affect comparisons between groups. The study supports an association with stabilization, but cannot tell us how the same patients would have done if assigned a different treatment.²

What the pooled estimate adds

A 2024 systematic review and meta-analysis included seven studies and 366 dutasteride-treated patients. Its estimated stabilization proportion was 62.8%, with a 95% confidence interval of 39.8% to 85.9%. That broad interval conveys substantial uncertainty around the pooled estimate.³

The review included the earlier 224-patient study, so these are overlapping bodies of evidence. Adding their participant totals would double-count patients. A pooled proportion also cannot remove the treatment-selection problems in the underlying observational studies. It is not a personalized probability of success or a randomized comparison with another medicine.³

Prescribing needs a separate discussion

In the United States, dutasteride capsules are approved for benign prostatic hyperplasia in men with an enlarged prostate. Use for FFA in women is off-label. The U.S. label’s adverse-effect frequencies from prostate studies should not be presented as rates established in women with FFA.⁴

Pregnancy is a contraindication because dutasteride can harm development of a male fetus. Women who are pregnant or may be pregnant should not handle the capsules. If contact with a leaking capsule occurs, wash the affected skin immediately with soap and water. Tell the prescriber about pregnancy possibility or plans before considering treatment.⁴

The UK regulator’s May 2026 update described the evidence linking dutasteride with psychiatric effects as very limited. It nevertheless called for a precaution about mood changes because these had been reported with finasteride, a medicine in the same class. It advises dutasteride users who develop depression or suicidal thoughts to contact a healthcare professional as soon as possible. This precaution should not be described as proof that dutasteride causes those effects.⁵

Make “working” measurable at follow-up

Ask the dermatologist which outcome will guide treatment decisions: front or temple recession, scalp inflammation, symptoms, or hair density. The study’s percentages cannot answer all four questions.

For your own record, take dated photographs from consistent front and side angles, include eyebrow changes, and note when each treatment started. Bring new itching, burning or tenderness to the appointment even if photographs look similar. FFA can also occur without noticeable symptoms.¹

Hair, Everywhere, Chapter 9’s “The Hairline That Moves Back,” discusses scarring hairline changes, their distinction from styling tension and why they need a dermatologist’s assessment. Its Hair Log can help keep photographs and treatment dates together for that conversation.